PI3K inhibitors are of potential clinical interest for the treatment of metaplastic BC, as suggested by a case report from the BELLE 4 clinical trial in which a durable response obtained in a patient with metaplastic BC following treatment with a combination of buparlisib (PI3K inhibitor) and paclitaxel [37]. This evidence concerns the gene PIK3CA and breast cancer.